Psyence Biomedical Ltd. Common Shares Cash Flow-to-Debt Ratio
Psyence Biomedical Ltd. Common Shares cash flow-to-debt ratio. Psyence Biomedical Ltd. Common Shares (PBM) has a Cash Flow-to-Debt Ratio of -0.05x as of December 2023, meaning its operating cash flow of $-662.00 could theoretically repay 0% of its total liabilities ($12.10K) in one year. Check Psyence Biomedical Ltd. Common Shares earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Psyence Biomedical Ltd. Common Shares (2022–2025)
Cash flow-to-debt ratio of Psyence Biomedical Ltd. Common Shares from 2022 to 2025. Historical debt coverage capacity for Psyence Biomedical Ltd. Common Shares across 4 annual periods. Also explore PBM shareholders equity momentum to track the company's year-over-year net asset growth rate.
Psyence Biomedical Ltd. Common Shares Cash Flow-to-Debt Ratio by Year (2022–2025)
Psyence Biomedical Ltd. Common Shares cash flow-to-debt ratio by year from 2022 to 2025. Year-by-year debt coverage analysis for Psyence Biomedical Ltd. Common Shares. For the full cash flow conversion analysis, see PBM cash flow metrics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -6.28x | $-3.73 Million | $594.37K | ▼ -2482.0% |
| 2024 | -0.24x | $-2.95 Million | $12.10 Million | ▼ -568.3% |
| 2023 | -0.04x | $-519.60K | $14.27 Million | ▲ +57.3% |
| 2022 | -0.09x | $-1.40 Million | $16.38 Million | — |